Home / Market News / $INSP
benzinga Corporate Catalyst Impact 65/100 ● neutral

Barclays Initiates Coverage On Inspire Medical Systems with Underweight Rating, Announces Price Target of $65

Oct 7, 2026, 12:48 PM UTC · Primary ticker $INSP

Barclays has initiated coverage on Inspire Medical Systems (INSP) with an 'Underweight' rating and a price target of $65. This new analyst coverage and negative rating could put downward pressure on INSP's stock price in the short term.

Barclays analyst Christopher Pasquale has initiated coverage on Inspire Medical Systems (INSP) with an 'Underweight' rating and a $65 price target. This is a significant event for INSP as new analyst coverage, especially with a negative rating, can influence investor sentiment and stock price. The 'Underweight' rating suggests Barclays believes the stock will underperform the broader market, and the $65 price target is likely below INSP's current trading price, indicating potential downside. This could lead to short-term selling pressure on INSP shares as investors react to the negative outlook. For traders, this presents a potential short opportunity or a reason to re-evaluate long positions, as the new coverage introduces a bearish perspective from a major financial institution.

$INSP negative Underweight rating and price target below current trading
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.